Clear cell renal cell carcinoma (ccRCC) is a kind of kidney cancer that occurs in the tubules that filter waste from the circulation. Under a microscope, the cancer cells appear as clear bubbles. The most frequent kind of kidney cancer is ccRCC.
Most kidney cancers like clear cell renal cell carcinoma develop for no known reason. But certain factors may increase your risk, such as:
Surprisingly, clear cell renal cell carcinoma usually won’t cause noticeable symptoms in its early stage. As the disease progresses, patients may experience:
One of the most commonly followed treatments regarding this issue is laser therapy. In fact, great success has been reported for laser treatment of squamous cell carcinoma. In this case, laser rays are obviously used to destroy cancer cells.
However, it is crucial to note that the right and highly professional execution of such a work demands the use of a proper and highly professional laser machine.
In this line, the FDA LASER-1.2A Portable Surgery 810nm Diode Laser System is one of the most recommended equipment among cancer surgeons due to its excellent efficacy in treating skin malignancies in particular.
To explain in more detail, this device’s blue laser light interacts better with the tissue components haemoglobin or melanin. At 980 nm (the high-level laser radiation needed), the machine performs better and gentler cutting, even at lower power.
Accordingly, its improved cutting performance makes it ideally suited to all surgical applications, particularly for kidney cancer.
What also makes the LASER-1.2A highly appreciated and recommended by surgeons is that it displays an accurate alignment and exact sighting during the treatment. All thanks to its green aiming beam.
To further improve the treatment, the device is supported with a fibre guide laser. So, it is compatible with various endoscopic uses. Also, these special fibres are sterilisable which, in turn, prevents any possible cross-infection while guaranteeing a clean and bloodless operative area.
With 980 nm wavelength and 15W as maximum power, the device is thought to perfectly address the Clear cell carcinoma issue. That is highly attributed to the fact that the LASER-1.2A uses infrared wavelengths and ultra-blue light to ensure high-level performance. That is also seen to reduce thermal damage and its peculiar interaction with haemoglobin.
Due to all these features, the LASER-1.2 A guarantees increased cutting effectiveness, much higher than the one obtained with infrared lasers.
According to studies, the 5-year survival rate of CCS ranges between 30 and 67 percent. CCS has a terrible prognosis since it spreads fast to other places of the body and frequently returns after therapy. This demands frequent check-ups and ongoing care. Fortunately, laser treatment has lately proven to be helpful in terms of early diagnosis and treatment of this specific condition, particularly since it has been a successful complement to cancer surgery in general.
In this context, we explored the advantages of laser treatment, namely the efficiency of LASER-1.2 A as a surgical laser device capable of effectively treating Clear cell carcinoma.
Reference: Clear Cell Renal Cell Carcinoma
Disclaimer: Although the information we provide is used by different doctors and medical staff to perform their procedures and clinical applications, the information contained in this article is for consideration only. SIFLASER is not responsible neither for the misuse of the device nor for the wrong or random generalizability of the device in all clinical applications or procedures mentioned in our articles. Users must have the proper training and skills to perform the procedure with each Laser System.
The products mentioned in this article are only for sale to medical staff (doctors, nurses, certified practitioners, etc.) or to private users assisted by or under the supervision of a medical professional.